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Abstract
The use of primary care electronic health records for research is abundant. The benefits gained from utilising such records 
lies in their size, longitudinal data collection and data quality. However, the use of such data to undertake high quality epi-
demiological studies, can lead to significant challenges particularly in dealing with misclassification, variation in coding and 
the significant effort required to pre-process the data in a meaningful format for statistical analysis. In this paper, we describe 
a methodology to aid with the extraction and processing of such databases, delivered by a novel software programme; the 
“Data extraction for epidemiological research” (DExtER). The basis of DExtER relies on principles of extract, transform 
and load processes. The tool initially provides the ability for the healthcare dataset to be extracted, then transformed in a 
format whereby data is normalised, converted and reformatted. DExtER has a user interface designed to obtain data extracts 
specific to each research question and observational study design. There are facilities to input the requirements for; eligible 
study period, definition of exposed and unexposed groups, outcome measures and important baseline covariates. To date the 
tool has been utilised and validated in a multitude of settings. There have been over 35 peer-reviewed publications using the 
tool, and DExtER has been implemented as a validated public health surveillance tool for obtaining accurate statistics on 
epidemiology of key morbidities. Future direction of this work will be the application of the framework to linked as well as 
international datasets and the development of standardised methods for conducting electronic pre-processing and extraction 
from datasets for research purposes.
Keywords Epidemiology · Computer science · Extract · Transform · Load · Observational study · Research methods
Background
Advancements in technology and healthcare systems has 
enabled large-scale collection of longitudinal electronic 
health records [1]. In the UK, there are many primary care 
databases (THIN, CPRD, QResearch and ResearchOne) of 
anonymised patient records [2, 3]. These datasets include 
information on demographics, practice registration related 
information, prescriptions, morbidity, lifestyle factors 
(height, weight, blood pressure, smoking and alcohol status) 
immunisation and laboratory test results [4]. The volume of 
data held in such datasets will continue to increase [5, 6].
Generally, the data within primary care databases are 
derived from healthcare software system used to manage 
patient’s clinical data [7, 8]. These systems are designed for 
the end-user experience of helping healthcare professionals 
to access and manage clinical data rather than for research 
purposes. As such, these datasets present several challenges 
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related to missing data, variation in definitions for diagnoses 
and incomplete and inadequate capturing of secondary care 
information [9–11]. However, the strength of these databases 
lies in their size, breadth, representativeness of the popula-
tion, long-term follow-up and sufficient data quality. Primary 
care databases offer great research potential related to drug 
safety and effectiveness research, identification of disease 
risk factors, generation of algorithms for identification of 
high risk patients, evaluation of public health policies and 
surveillance of diseases [4, 12–16]. In recent years, there is 
an increase in trend of using such routinely available data in 
healthcare research [3, 17].
In research which utilises primary care databases, data 
pre-processing and extraction are important steps of trans-
forming the available raw data into a format suitable for 
statistical analysis. The process of extraction of primary care 
data for research is expensive due to time, effort and exper-
tise required [11]. Factors such as; database size, database 
structure, range of available data, level of detail, complex-
ity of study designs and study variables (such as exposure, 
outcome, inclusion or exclusion criterion and potential 
confounders) makes data extraction a complex process. It 
requires experts with considerable clinical, scientific and 
technical expertise to interrogate primary care databases 
[18]. A sound communication and documentation process 
is also important between researchers and data extraction 
experts to reduce human induced errors, and to minimize 
any biases that may occur in extracted data set because of 
miscommunication or difference in understanding. Data sup-
pliers may offer extraction services for a fee, or research-
ers may collaborate with in-house specialists available to 
carry out extraction. There are no standard methodologies 
one can follow to extract data from primary care databases. 
An initial extraction may be based on patient restrictions, 
inclusion and exclusion criteria and multiple other extrac-
tions are performed to obtain additional variables. Experts 
use various software to manually compile an analysable data 
set for each study. This non-standard and non-automatic 
way of data extraction is labour-intensive; adds constraints 
on accuracy and reproducibility of results; and has limited 
methods to verify the validity and integrity of the datasets 
generated. Some corporate as well as University bodies have 
made considerable progress in trying to deliver solutions 
to manipulating electronic health record data. The rEHR 
R package, and The European Health Data & Evidence 
Network’s (EHDEN) Observational Health Data Sciences 
and Informatics (OHDSI) platform ATLAS are examples of 
software available to support researchers in extracting data 
taken from primary care [19, 20]. However, these packages 
and tools requires substantial user manipulation, statistical 
background and programming expertise which clinicians 
may lack and/or lacks certain features such as data extrac-
tion based on particular study designs and the ability to 
match cohorts. Aetion is an example of an alternate corpo-
rate provider of readily analysable datasets using longitu-
dinal healthcare data, however, the mechanism and schema 
of their approach has not yet been published, therefore the 
validity and reproducibility of their approach is currently 
unclear [21].
In spite of best efforts, data extraction from primary 
care databases poses a number of issues; technical, human 
dependent, non-automatic, time consuming, need for data 
cleaning, handling very large data sets and complex logic 
with no room for verification and validation of the generated 
data. With advances in technology, there is clear scope in 
improving current methods of designing studies and extract-
ing data. In particular, considering the importance of data in 
medical research, it is crucial to create automated methods 
to extract verifiable and valid datasets to expedite research 
and to avoid human induced errors.
In this paper, we introduce DExtER, an extract transform 
load (ETL) based software framework that enables auto-
mated clinical epidemiological studies (ACES), in a repro-
ducible and verifiable way. This system potentially allows 
the stakeholders to extract high quality, patient-based data 
from primary care databases and hence enables a large range 
of research possible with electronic primary care data that 
could be translated to other healthcare databases.
Methodology
Extract, transform and load (ETL)
ETL [22] processes are backbones of data warehousing. 
Application of ETL is not new in medical research [23–26]. 
ETL performs three distinct steps; extraction of data from 
source system, transformation of data and loading of data 
into target system.
‘Extraction’ is a simple process, in which depending 
on what stage the data is needed and what data is needed, 
tailored subset of data that is necessary for the subsequent 
transformation stage is extracted from specific parts of the 
data source. Extraction can be from multiple sources (multi-
ple primary care databases or a combination of primary and 
secondary care databases) and from any form of technologi-
cal infrastructure (or a combination of them) in which the 
data is being stored (e.g., RDBMS, NoSQL, spreadsheets 
and flat files).
During ‘Transformation’ a number of operations can 
take place e.g., conversion, filtering, reformatting, appli-
cation of a number of special-purpose business rules and 
aggregation. It is important to identify and note some of the 
schema level and instance level challenges that may occur 
during transformation [27]. For example, as the system 
allows multiple data sources, conflicts in naming can occur 
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where same name might identify different things in the data 
sources. Different primary care databases may use differ-
ent clinical coding systems (Read codes vs ICPC: Interna-
tional Classification of Primary Care). Value level problems 
may exist such as different date formats or HbA1c being 
expressed in  % as opposed to mmol/mol. Converting data 
structure and semantics of various databases into one com-
mon format, for example OMOP CMD [28], helps to solve 
some of these issues. The benefits of such unified data model 
has already been well researched [28–30].
Alternatively, several operations such as conversion, 
normalization and reformatting are accommodated in the 
transformation steps. Finally, in the ‘Load’ step, the result-
ing transformed data gets pushed into the target systems or 
file formats.
Flow of control and application to observational 
study design
Our system is based on observational (cohort, case–control, 
and cross-sectional) study designs. Although, the core prin-
ciples of each observational studies are somewhat similar 
(observational in nature without introducing an interven-
tion), they do have certain steps that do differ in terms of 
exposure definition, the need for controls and how they 
manage time. Hence the first step towards automating data 
extraction was to map out steps performed in these study 
designs. For example, a cohort study requires an exposed 
and unexposed group which are both followed up until a 
point of outcome or study end date.
Instead of creating a different ETL workflow for each 
study design, we identified common extraction steps and 
merged them while allowing necessary branches for steps 
unique to each design. This way we were able to create a 
single workflow model (Fig. 1) that is applicable for all the 
three study designs and understand the primary flow of con-
trol (ordered sequence of steps) that describes the route of 
data from the sources to the target, and intermediate trans-
formations along the workflow. Defining this flow of control 
is essential for implementation and serves as the conceptual 
design of our novel model [31, 32] (i.e., the process of iden-
tifying the sources and the target systems, and determining 
the appropriate transformations).
Figure  1 also represents the ETL workf low and 
illustrates primary care database sources (PC DB1 and 
PC DB2), which could represent any electronic health 
record dataset. The raw data from each source propagates 
through different workflow stages of the system based on 
the study design and user input criteria. Depending on 
selected study design and input criteria, the extraction 
process may not involve all the transformation stages. For 
example, in a cross-sectional study, there is no control 
Fig. 1  ETL workflow
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selection, outcome definition or matching required, and 
hence the extraction process would skip these stages. 
Before each transformation stage begins, an extract step 
will fetch tailored data from specific parts of the raw data 
sources based on the input criteria. After each stage of 
the transformation process, there are intermediate data 
stores that holds the transformed data until it propagates 
to the next stage. The intermediate data stores can be in-
memory data structures (such as RAM) or can be stored 
in physical memory; the latter option are helpful in the 
case of a failure, where the whole process need not be 
started from the beginning. Ultimately, raw data is trans-
formed into analysable datasets and loaded into the target 
system. An important process at the end of each transfor-
mation step is to document the reason why some patient 
records may be rejected and do not qualify for further 
processing. This documentation process is crucial and 
of immense importance, to ensure that data produced by 
the system is verifiable and valid, often a step which is 
not as easily achieved through other means. This process 
informs stakeholders of why patients were filtered out 
at various stages of data extraction and the reason for 
rejection. Another important feature of our model is its 
modular nature. Modularity of the system allows flexibil-
ity in terms of error handling, logic implementation, and 
provides ease to add new workflow stages (for example, 
a new workflow stage to clean the data set). A specific 
transformation stage of importance is added to encrypt 
the datasets using Advanced Encryption Standard (AES) 
256-bit cipher as a data privacy step.
Stages of study design input using DExtER
A pre-requisite for using the system to extract data is to 
come up with a well-defined set of inputs, ranging from; 
study period, study population, study variables (exposure, 
outcome and covariates), requirement of controls with 
matching criteria and the baseline characteristics with 
the outcome(s) of interest. In our implementation of the 
system, we have built a web-based HTML UI for users to 
provide these inputs, and we save the input in database 
and supply it to the system for data extraction based on a 
FCFS (First Come, First Serve) queue and hence provide 
multiuser facilities. The primary care database we used 
was ‘The health improvement network’ (THIN) database 
[33]. We have been able to test and validate the system on 
the Clinical Practice Research Datalink (CPRD) GOLD 
[34] and CPRD Aurum [35]. Our system is applicable to 
any observational healthcare database which is similar in 
structure and semantics to CPRD, THIN or observational 
medical outcomes partnership (OMOP) common data 
model (CDM).
Stage 1: Defining study eligible period
The first stage of the system is the process of defining eli-
gible period for the study (Table 1). This eligibility period 
is composed of the patient start and end date, and it is in 
between this time duration in which all the events of interest 
(exposure, outcome) take place. In this step, we define the 
age and sex requirements of the group (e.g. in a study about 
pregnant woman we usually require only females of the age 
group 13–50 years) and apply data quality filters (e.g. adding 
days to keys dates of adequate computer usage) to improve 
the integrity of the raw data [36, 37].
Stage 2: Defining the exposed group in cohort design 
or cases in case–control design
The next stage is to define the exposed/case group as the 
system assigns each patient an index date based on single or 
multiple exposure (Table 2). In this step we employ a recur-
sive descent parser (a mathematical tool used to determine 
if a sequence of symbols such as sentence is syntactically 
correct) [38], and a regular grammar (set of rules used to 
define the syntax for a particular language) [39] to success-
fully identify any number of exposures. If the study has more 
than one exposure, then we propose two modes of parsing 
namely strict parsing and loose parsing. The former is used 
when the order of occurrence of each exposure is relevant 
to the study (for example, in one of our study the expo-
sure was diabetic patients who were prescribed a particular 
medication [40]), if otherwise, the latter is selected. If the 
study requires unexposed group/controls, patients who do 
not belong to the exposed group are labelled as potential 
unexposed group/controls. In supplementary 1 we discuss 
the proposed regular grammar.
During implementation of the system we have trialled 
some advanced study designs such as whether the exposure 
considered is only incident patients compared to occasions 
where we have explored incidence and prevalent cases par-
ticularly where the exposure is rare [40–44]. Current work 
involves implementing pharmaco-epidemiolocal study 
designs such as new [45] and prevalent new-user designs 
[46].
During this stage it is also important to understand how to 
manage the outcome variables. If the study requires patients 
to be removed if an event of the outcome has occurred before 
the index date, then the workflow stage for determining 
outcome(s) is executed right after each time an index date is 
assigned to the patient and then patients are removed if the 
outcome has occurred before index date. If the study does 
not have any restriction on the patient based on the outcome 
the workflow stage for determining outcome(s) is executed 
before the last stage.
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Stage 3 and 4: Defining the control group and matching
The control selection stage (stage 3) executes only if the con-
trols are required for the study (Table 3). We note that unex-
posed/control group can still have exposure(s). Although 
the index date for controls depends on the clinical question 
and study design, in most studies the corresponding exposed 
patient’s index date is assigned to the control patient to miti-
gate immortality time bias [47].
The matching stage (stage 4) of the ETL workflow is 
employed where controls are required for the study and 
they need to be matched on specific parameters (Table 4). 
The matching criteria in each epidemiological study var-
ies dependent on the study design. Parameters such as age, 
sex, and practice-based matching are common, some criteria 
such as matching disease duration (example diabetes dura-
tion), matching variable values (e.g. HbA1c or BMI) are 
also required at times. In our implementation of the system 
we have provided a range of matching criteria such as the 
number of unexposed/controls needed per exposed/case; 
should unexposed/control come from the same practice or 
from randomly selected practices; and what parameters they 
need to be matched on (e.g. age, gender and other variables 
described above).
We have developed the UI so that users can enter appro-
priate inputs for each of them. The matching stage of the 
workflow works in two steps. In the initial step, for each 
exposed/case in the study we identify and mark a list of 
unexposed/controls who pass the matching criteria. In the 
next step, we randomly (to avoid any biases) select the 
required number of controls for the exposed/case from 
the initial list and mark them as group by assigning them 
a unique number. Remaining unexposed/controls are 
unmarked and are available as potential controls for the other 
exposed/cases.
Stage 5: Determining outcome and defining patient exit 
date
This process introduces a new variable called the patient exit 
date (Table 5), which is by default the patient end date unless 
the study has an outcome in which case the patient exit date 
Table 1  ETL stage 1: defining study eligible period
ETL stage 1 user inputs
# Variable name Data type Example
1 Study start date Calendar date 15/01/1998
2 Study end date Calendar date 15/12/2019
3 The number of days that should be added to key dates (Computerization/Acceptable Mortality Rate/
Healthcare System) of the practice (optional)
Numeric 365
4 The number of days the patient should be registered in the practice before inclusion in the study (optional) Numeric 365
5 Age at cohort entry Numeric 25–84
6 Maximum allowed age at cohort exit Numeric 115






ETL stage 1 transformation logic
Transformation logic
1. For each practice present in the database repeat the following
  • Add the number of days to key dates (input #3)
  • Practice start date = latest date of (key dates, Study Start Date)
  • Practice end date = earliest of (Study End date, Collection date)
2. For each patient record present in the eligible practice, repeat the following
  • Add the number of days to Registration date of the patient if input is supplied (input #4)
  • Patient start date = latest date of [Registration date, Practice Start Date, date the patient attains minimum age at cohort entry (input #5)]
  • Patient end date = earliest date of [Practice End date, Deregistration date, Death date, date the patient attains maximum age allowed at 
cohort exit (input #6)]
  • If patient is at least minimum age years old at patient start date, but not older than maximum age years old go to next step
  • If patient’s sex is same as what is supplied in input 7, go to next step
  • If patient start date is before practice end date and patient end date is after practice start date, store the patient record for the next stage else 
reject
3. Document reason for rejection
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is set to the date on which the outcome occurred. This stage 
is also responsible to extract any outcome required for the 
study for all eligible patients.
Stage 6: Baseline variables and assembling an analysable 
dataset
The last stage of the workflow is extracting baseline vari-
ables that are required for the study (Table 6). This is a sim-
ple extract step where for each patient the required variables 
(e.g. BMI, glucose levels) are extracted from the raw data 
sources based on the input criteria (example if the latest 
value is required or if the earliest value is required). This 
stage also hosts a final Load step, which assembles all the 
study variables from corresponding intermediate data stores 
(previously extracted and transformed at different stages of 
the workflow) as the analysable dataset. We also propose 
encrypting the generated datasets to standards set by NHS 
to enforce data protection.
At the end of the process, we provide the reason for rejec-
tion of the discarded patients. This process is executed each 
time a patient is discarded. Here we employ a map data 
Table 2  ETL stage 2: Defining the exposed group in cohort design or cases in case–control design
Defining code entities
In electronic health records all diagnoses, symptoms, treatment, physical and laboratory measurements are coded into the system using some 
sort of clinical coding system, for example in Vision and EMIS systems, Read codes are used to record all diagnoses and symptoms. In HES 
records OCPC and ICD10 codes are used for the same purpose
In this section we introduce a code entity which encapsulates clinical code that represents diagnoses, symptoms, treatment, physical or labora-
tory measurements etc. and some properties that describe it’s use and characteristic. The properties of Code Entities will change slightly 
depending on which ETL stage it is being used
Code entity for exposure
# Variable Data type Example
1 Name Text Type2Diabetes




3 Exposure type Categorical with following levels
For inclusion criteria
  • Incident only
  • Incident or prevalent
  • First record after cohort entry
For exclusion criteria
  • Exclude if ever recorded




  • Exclude if ever recorded
4 Definition Delimited text Read code for Type 2 diabetes:
C10F.11, C10F.00
ICD10 for Type 2 diabetes:
E110
ETL stage 2 user inputs:
# Variable name Data type Example
1 Code entity Code entity of exposure Name: Type2 Diabetes
Criteria: Inclusion criteria




Exposure type: Incident only
Definition: {6.1.2.2}
2 Combination logic of the exposure Text: formatted as regular grammar suggested Type2Diabetes and Metformin




4 Exclude patients if these outcomes occur 
before index
Code entity (list) Ischemic heart disease
Stroke
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structure that maps reason for rejection to number of patients 
discarded for that reason. When the system encounters a 
patient, who is to be discarded, first it looks in the map to 
see whether it already contains the (key) reason for rejection 
which triggered the process. If present, then the value against 
this reason is incremented by one and patient is discarded. If 
the reason is not already present, then it is newly entered in the 
map, and the corresponding value is set to 1. This way we will 
be able to record all the patients who are rejected and the exact 
reason behind why they were rejected. Optionally, we can 
also log details of the patient to manually verify the rejection.
Implementation on site
We have implemented DExtER as a 3-tier web-based soft-
ware system. We have built a website as the front end where 
stakeholders of the system can login and use the UI to sub-
mit their study design and data extraction requests which 
are stored in a database. The middleware of our system is 
the data extraction software written in Java. The middleware 
processes the data extraction requests on a first come, first 
serve basis and notifies users when the data extraction is 
complete. The backend of the system is Postgres RDBMS to 
store THIN database available to our institution.
Data protection and privacy
Data protection and privacy policies are important pre-req-
uisites for any successful tool. Therefore, the web interface 
we developed for this tool are line with the University of 
Birmingham data regulation guidance and works within the 
principles set out by the Information Commissioners Office 
[48]. Prior to any data extraction, the study design must have 
gone through ethical approval. Following which, in accord-
ance with the protocol sent for ethics, a minimum dataset is 
extracted. A data extraction log (audit) is created each time 
an extraction is attempted. Following extraction, the dataset is 
encrypted to AES 256 using a password supplied to the user.
Discussion
To date we have conducted a wide variety of epidemiological 
studies to both validate our tool and shed light on complex 
clinical questions. This research has been conducted as part 
of funded investigator led research, doctoral research and 
postgraduate taught course dissertations. The results of such 
studies have culminated in over 35 peer-reviewed publications 
in high impact factor general medical and specialist journals 
in the last 2 years, with more than 25 studies currently ongo-
ing simultaneously. We highlight some of the studies, present 
comparable research elsewhere as a source of validity and 
discuss their clinical and public health importance below.
Utility and validity of DExtER
A summary of validation of the tool can be seen in sup-
plementary 2. In our first study utilising the DExtER tool 
Table 2  (continued)
ETL stage 2 transformation logic
Transformation logic
Repeat the following for each eligible patient record present from previous stage
  • For each code entity with inclusion criteria if the exposure type is
    ○ Incident only: find the earliest event of the code entity before patient end date and save details if found, if the event is before patient start 
date exclude patient and document reason for exclusion
    ○ Incident or prevalent: find the earliest event of the code entity before patient end date and save details if found
    ○ First record after cohort entry: find the earliest event of the code entity after the patient start date and before patient end date and save 
details if found
  • The parser in the system based on the combination logic supplied does the following each time it encounters a code entity of the patient
    ○ If all inclusion code entities are found in the patient go to next step, else if controls are required mark patient as ‘potential control’ else 
discard the patient and document reason
    ○ If the parsing mode is loose, latest event date among the code entities is set as patient’s index date
    ○ Else if the parsing mode is strict, If and only if the code entities have occurred in the same order as defined in the combination logic, set 
patient’s index date as date of latest entities’ event date else discard the patient and document reason for rejection
  • For each code entity with exclusion criteria if the exposure type is
    ○ Exclude if ever recorded: find the event described by the code entity, if the entity is found exclude patient and record documentation for 
rejection
    ○ Exclude if recorded before index date: find the event described by the code entity before patient’s index date, if the entity is found exclude 
patient and record documentation for rejection
  • Exclude patients if these outcomes occur before index
    ○ For each code entity in the list check if it occurs before index date, if the entity is found exclude patient and record documentation for 
rejection
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we explored the association between Type 1 Diabetes and 
subsequent risk of developing epilepsy using a cohort study 
design [49]. Previous literature were mainly case studies 
or case control in nature [49–52]. One study explored the 
association in a cohort design but the study was from a low-
middle income country, where there are other confounding 
factors that may have resulted in the observed association. 
[53] In our study we identified exposed patients in THIN 
database with a diagnosis of Type 1 Diabetes and matched 
them to four unexposed patients by age, gender and gen-
eral practice location. After following both sets of patients 
for, on average, just over 5 years, we were able to identify 
how many patients in each group developed epilepsy. The 
incidence rate (IR) of the development of epilepsy in the 
unexposed group was 44 per 100,000 person years. This 
rate is similar to published literature, as a recent systematic 
review described the IR to be 50/100,000 person years in 
developed countries globally [54] This was compared to an 
IR in our exposed group of 132/100,000 person years, result-
ing in an overall adjusted Hazard ratio (HR) of 3.01 (95% 
CI 1.93–4.68). This threefold increased risk was similar to 
cohort study from Taiwan (HR 2.84; 95% CI 1.95–4.69) 
[53].
We have conducted similar retrospective cohort study 
designs to report on outcomes including for rare diseases 
such as Achalasia [15] and IgA vasculitis [41]. For IgA vas-
culitis we identified patients with the child onset and adult 
onset IgA vasculitis and identified following adjustment that 
these patients had an increased risk of developing hyperten-
sion (Child onset: HR 1.52; 95% CI 1.22–1.89; Adult onset: 
HR 1.42; 95% CI 1.19–1.70) and chronic kidney disease 
(Child: HR 1.89; 95% CI 1.16–3.07; Adult: HR 1.54; 95% CI 
1.23–1.93) [41]. With a similar study design, we identified 
that the diagnosis of the oesophageal condition achalasia 
was strongly associated with the development of oesopha-
geal cancer and lower respiratory tract infections [15]. The 
findings in both of these studies are useful to clinicians as we 
can shed light on novel associations which are important to 
consider in clinical management and long-term surveillance.
These two manuscripts also highlight another application 
of the DExtER tool, which we have since utilised. We were 
also able to study yearly incidence and prevalence of these 
conditions using yearly cohort and cross-sectional study 
designs respectively. We noted that the incidence of IgA vas-
culitis was stable but the documented prevalence in the gen-
eral population was increasing. In our Achalasia study, we 
Table 3  ETL Stage 3: Defining the control group
This stage is very similar to the previous stage in many ways. The he definition of the code entity remains the same as in the previous stage
ETL stage 3 user inputs
# Variable name Data type Example
1 Code entity Code Entity of exposure Name: Type2Diabetes
Criteria: Inclusion criteria
Exposure type: Incident only
Definition: {C10F.11, C10F.00}
2 Combination logic of the exposure Text: formatted as regular grammar suggested Type2Diabetes




ETL stage 3 transformation logic
Transformation logic
Repeat the following for each eligible patient record marked as ‘potential control’ from previous stage
  • For each code entity with inclusion criteria if the exposure type is
    ○ Incident only: find the earliest event of the code entity before patient end date and save details if found, if the event is before patient start 
date exclude patient and document reason for exclusion
    ○ Incident or prevalent: find the earliest event of the code entity before patient end date and save details if found
    ○ First record after cohort entry: find the earliest event of the code entity after the patient start date and before patient end date and save 
details if found
  • The parser in the system based on the combination logic supplied does the following each time it encounters a code entity of the patient
    ○ If all inclusion code entities are found in the patient go to next step, else discard the patient and document reason
    ○ If the parsing mode is loose, latest event date among the code entities is set as patient’s index date
    ○ Else if the parsing mode is strict, If and only if the code entities have occurred in the same order as defined in the combination logic, set 
patient’s index date as date of latest entities’ event date else discard the patient and document reason for rejection
  • For each code entity with exclusion criteria if the exposure type is
    ○ Exclude if ever recorded: find the event described by the code entity, if the entity is found exclude patient and record documentation for 
rejection
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were able to compare the documented IR from THIN data to that obtained from the Hospital Episodes Statistics. They 
Table 4  ETL Stage 4: Matching
In this step we match and assign controls to the exposed/case groups that we have defined in the previous two steps. In this stage we ignore the exposure type and criteria 
properties of the code entities
ETL stage 4 user inputs
# Variable name Data type Example
1 Number of controls required for each exposed Numeric 4
2 Plus, or minus how many years old can the control be compared to exposed Numeric 1





4 Plus or minus how many days should we match on registration date Numeric 365












8 Which exposure duration to match for and for how long (in days)? Code entity, numeric Type2Diabetes, 365
9 Match for conditions at baseline, if yes what to match for? Code entity Hypertension
10 Match for treatment at baseline, if yes what to match for? Code entity Aspirin
10 Match for physical measurements if yes with-in what time duration (in days) and to plus or 
minus what value?
Code entity, numeric, numeric BMI, 735, ± 2
11 Match for laboratory results if yes, with-in what time duration (in days) and to plus or minus 
what value?
Code entity, numeric, numeric HBA1C, 735, ± 2
12 Exclude patients if this outcome event occurs before index date Code entity (list) Stroke TIA
Ischemic heart disease
13 Exclude patients if this event occurs before index date Code entity (list) Obstructive sleep apnoea
ETL stage 4 transformation logic
Some of the steps described below may not be executed depending on the input supplied by the user. For example, if the user does not wish to 
match for Townsend then matching for Townsend step would be skipped from execution
Transformation logic
1. Randomise the list of exposed patients and the list of potential controls
2. After randomisation repeat the following for each exposed
  • Filter out all potential controls based on supplied sex matching criteria
  • Filter out all potential controls whose patient end date is before exposed/case’s index date or patient start date is after exposed/case’s index 
date
  • Calculate age as on exposed/case index date for all remaining controls. Filter out all potential controls if their they are too old or too young 
based on the given input criteria
  • Filter remaining potential controls based on given Townsend matching criteria
  • Filter remaining potential controls based on given Ethnicity matching criteria
  • Filter remaining potential controls based on given Exposure duration matching criteria
  • Filter remaining potential controls by removing everyone who are not on the same treatment (from the input list supplied) as that of exposed
  • Filter remaining potential controls by removing everyone who are not on the same treatment (from the input list supplied) as that of exposed
  • Remove all potential controls who are not on the same treatment (from the input list supplied) as that of exposed/case before exposed/case’s 
index date
  • Remove all potential controls who do not have the underlying conditions (from the input list supplied) as that of exposed/case before 
exposed/case’s index date
  • Filter remaining potential controls by removing everyone whose required physical measurement and/or laboratory results are not with-in the 
range specified and with-in the time scale specified as that of the exposed/case
  • Filter remaining potential controls by removing everyone who has a record of outcome and/or record of an event specified on or before the 
exposed/case’s index date
3. In the list of remaining controls randomly pick as much as number of controls required per exposed/case and assign them an index date 
which is the same as exposed/case and remove them from the main list of potential controls (for a without replacement control selection)
4. Assign each exposed/case and their controls a group id
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were broadly similar (HES was 1.99 (95% CI 1.87–2.11) and 
1.53 (95% CI 1.42–1.64) per 100 000 person-years in THIN), 
with observed difference potentially attributed to the differ-
ing population structure and incomplete recording of the 
condition in primary are settings. One of our publications on 
atrial fibrillation prevalence trends from 2000 to 2016 was 
extracted by a senior data scientist in the usual conventional 
manner by manually writing a programme using STATA 
software [55]. We compared the prevalence calculated by 
the data scientist to that obtained using DExtER, in the same 
year but using the latest version of the THIN database. Both 
were identical, for example both showed a prevalence of 
3.3% in adults aged 35 years and older in 2016.
DExtER as a public health surveillance tool
The scope and use of automated cohort and cross-sectional 
designs has the potential of being an extremely important 
assert in Public Health settings and drug safety surveil-
lance centres. Working with colleagues in Public Health 
England (PHE) we have compared the prevalence the tool 
generates to that reported in Quality Outcome Framework 
and again we found that they were similar to prevalence 
observed from other UK data sources. We have now imple-
mented the tool in PHE for generating key incidence and 
prevalence figures that will aid with service planning and 
resource allocation, and for further independent evalua-
tion. As part of the agreement with PHE, they will be inde-
pendently validating the use of the tool. The tool can also 
be used for surveillance of beneficial and adverse effects 
of medications, early on after introduction of new thera-
peutic agents and over a long period of time for outcomes 
such as cancer and cardiovascular events. For example we 
were able to explore whether benefits from medications 
demonstrated in clinical trials (such as the Empagliflozin 
EMPA-REG trial [56]) can be replicated in real-world set-
tings. Sodium-glucose transport protein 2 inhibitors were 
found to decrease mortality in patients with previous car-
diovascular disease in this trial. We were able to explore 
this in THIN database and found that patients who were 
given SGLT2 Inhibitors were significantly less likely to die 
of any cause irrespective of baseline CVD status (adjusted 
IRR 0.50; 95% CI 0.33–0.75) [14]. This specific finding 
was replicated by another large real world evidence study 
(CVD-REAL HR 0.49; 95% CI 0.48–0.60 [57]).
Future directions, benefits, limitations and ethical 
considerations
We are now progressing the work towards automation for 
complex study designs through a work programme named 
Automated Clinical Epidemiology Studies (ACES), partly 
funded by Health Data Research (HDR) UK through a fel-
lowship [58]. Additionally, through HDR UK, our team 
was involved in two successful digital innovation hubs 
(INSIGHT and PIONEER) [59]. As part of the INSIGHT 
hub funding, the tool is now also being adapted to include 
bespoke eye hospital data and provide further learning 
opportunities into the flexibility, benefits and limitations of 
the tool particularly for datasets not configured for use in 
observational research.
As part of the HDR fellowship work, we will apply the 
framework for pharmaco-epidemiology study designs, linked 
primary–secondary care databases and for databases with 
linked mothers and babies. How each of these can be incor-
porated into DExtER depends on what information should 
be extracted from them and can vary drastically depending 
on the research question. The important thing to note is that 
the modular nature of the tool allows the addition of new 
stages containing specific rules and complex scenarios to 
its current set to facilitate such datasets. For example, the 
tool has the capacity to conduct a study involving primary 
care and hospital episode statistics where a researcher maybe 
interested at looking readmissions to the hospital but may 
Table 5  ETL Stage 5: Determining outcome and defining patient exit date
In this stage we ignore the exposure type and criteria properties of the code entities
ETL stage 5 user inputs
# Variable name Data type Example
1 Outcome Code entity (list) Ischemic heart disease
Stroke
Heart failure
ETL stage 5 transformation logic
Transformation logic
For each patient from the previous stage, repeat the following
  • Set value of patient exit date to that of patient end date
  • Look for first event of required outcome(s) before patient end date and after patient’s index date
  • Assign exit date as date of the first outcome for each patient
Data extraction for epidemiological research (DExtER): a novel tool for automated clinical…
1 3
want to look in the primary care for the baseline variables. 
In such scenarios it is possible to add a new modular stage 
with bespoke UI to DExtER to facilitate this study design. 
We will also apply our tool to databases in other settings and 
countries, resulting in a global community who can collabo-
rate and generate reproducible research across several data-
bases. For example, we have evaluated its ability in the RNH 
(Registration Network for General Practitioners) database 
in Netherlands and found it to work seamlessly. The main 
benefits of the system are it provides researchers fast, effi-
cient and reliable data extraction capacity. It eliminates the 
IT expertise required to extract datasets manually. The pro-
posed ETL based architecture works as a standard to extract 
data for epidemiological studies and extracting data in this 
automated and standard way highly promotes reproducible 
research which is hard in epidemiology [60]. The documen-
tation why patient records were discarded establishes data 
integrity, credibility and renders the dataset valid and veri-
fiable. The tool has its limitation such as not being able to 
cater for all possible different subtle designs an epidemiolo-
gist may consider eliciting an association or methodologies 
to reduce biases in specific contexts. The tool can only be 
used with sound knowledge of epidemiological principles, 
otherwise may result in numerous spurious and potentially 
incorrect findings. The ability to conduct studies within 
hours could result in publication biases where researchers 
may choose to undertake studies with a prior knowledge of 
the likely outcome or chose to ignore pursuing studies with 
negative outcomes [61]. To avoid this, the team will aim to 
conduct workshops involving key stakeholders to build an 
ethical framework that mitigates these unintended conse-
quences of ACES. To facilitate global research, currently the 
tool can be made available for research at academic institu-
tions anywhere in the world, subject to a negotiated contrac-
tual licence with the University of Birmingham (contact the 
corresponding author for further details).
Conclusion
In the recent years, there is an increasing trend in the use 
of routinely available data in the field of epidemiology. 
Primary care databases supply researchers with large 
amounts of medical data and the potential to answer 
several different research questions using various study 
designs. However, nonstandard and manual data extraction 
from primary care databases is complex, labour intensive 
and time-consuming process. Currently existing solutions 
such as the rEHR package and EHDEN’s ATLAS [19, 20] 
attempt to overcome the need for manual extraction, but 
these options still require substantial programming skills 
(need for expertise and prone to human error) and are 
limited in its applicability to various study designs and 
matching options. Whereas in this paper, we have been 
able to present an ETL based framework (DExtER), a 
tool used to automate the process of data extraction for 
epidemiological research based on study designs which 
Table 6  ETL Stage 6: Baseline variables and assembling analysable dataset
In this stage we ignore the exposure type and criteria properties of the code entities
ETL stage 6 user inputs
# Variable name Data type Example





ETL stage 6 transformation logic
Transformation logic
For each patient from the previous stage, repeat the following
  • Extract the required baseline variable




    ○ Any matching information
    ○ Baseline characteristics
    ○ Outcomes
  • Encrypt the data using cipher supplied by user and write data to file/database
  • Exit process
 K. M. Gokhale et al.
1 3
can utilise any longitudinal primary care electronic record 
source. Corporate solutions which can provide a similar 
service to DExtER, [21] are yet to publish the developed 
algorithms/programs, and hence they are limited in the 
validity of their techniques and reliability in the datasets 
generated for research. Whereas, DExtER provides a non-
invasive solution to generate quality datasets in an ana-
lysable format through a process that can be verified and 
reproducible.
We anticipate this new architecture will expedite and 
reduce the costs of epidemiological and health services 
research by reducing the gap between medical research-
ers and electronic patient records. As a part of the future 
work, we want to develop concrete standards for each step 
in the data extraction process and work towards developing 
automated analytics with the vision to create an automated 
research pipeline for epidemiological studies.
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